Dependence on cell and gene therapy program activity
Clinical and commercial programs can be delayed, canceled, or scaled back, reducing demand for specialized logistics and storage.
- Scope
- BioLogistics and BioStorage demand
- Materiality
- high
Cryoport, Inc.
Cryoport, Inc. provides temperature-controlled supply chain solutions for the life sciences industry, with a particular focus on cell and gene therapies. The company combines logistics, biostorage, bioservices, cryopreservation, and cryogenic equipment manufacturing to help customers move and store sensitive biological materials under tightly regulated conditions.
−5,2 %
47,1 %
44,4 %
2.17
2.07
| % | |
|---|---|
| Life Sciences Services | 54.8% Temperature-controlled logistics, biostorage, bioservices, and cryopreservation for life science customers. |
| Life Sciences Products | 45.2% Cryogenic systems such as freezers, dewars, and related accessories sold directly or through distributors. |
Cryoport sells primarily to life sciences customers that need validated, compliant handling of sensitive biological...
- Biotechnology and pharmaceutical companiesprimary
Buy logistics, storage, and cryopreservation services for clinical and commercial biologics, especially CGT programs.
- Contract research organizations and CDMOsprimary
Use Cryoport to move trial materials and support outsourced development/manufacturing workflows.
- Clinical trial sponsorsprimary
Need compliant, traceable transport for patient- or donor-derived materials across global trials.
- Fertility and reproductive medicine providerssecondary
Buy cryopreservation and temperature-controlled handling for reproductive materials.
- Animal health and research institutionssecondary
Purchase cryogenic systems and logistics for biological samples and research materials.
Cryoport generates most of its revenue in the Americas, with meaningful exposure to EMEA and APAC...
- •Americas accounted for 74.5% of 2025 revenue
- •EMEA accounted for 14.3% of 2025 revenue
- •APAC accounted for 11.2% of 2025 revenue
- •International sales expose the company to FX and trade/regulatory risk
- •DHL partnership is intended to strengthen EMEA and APAC reach
Cryoport is focused on deepening its position in cell and gene therapy supply chains by combining digital logistics,...
01
Grow in cell and gene therapy supply chainsmedium-term
CGT programs require specialized, validated logistics and create sticky customer relationships.
02
Digitize and integrate the operating platformmedium-term
A unified digital layer improves visibility, compliance, and execution across global shipments and storage.
03
Rebalance the international network after CRYOPDP divestitureshort-term
The divestiture frees capital and allows focus on higher-value services and strategic partnerships.
Cryoport faces execution risk from its dependence on regulated life sciences demand, especially CGT programs that can...
Need for continued external capital
The company expects near-term operating losses while investing in growth, which may require equity or debt financing.
- Scope
- Liquidity and acquisition capacity
- Materiality
- high
Foreign currency and international operating risk
Revenue and costs in Europe and Asia are exposed to exchange-rate swings, local regulation, and geopolitical disruption.
- Scope
- EMEA and APAC operations
- Materiality
- high
Customer concentration
A single customer represented 10.2% of total revenue in 2025, which can create volatility if volumes change.
- Scope
- Life Sciences Services segment
- Materiality
- high
U.S. federal funding disruption
Some customers rely on federal funding or agency oversight, and shutdowns can delay purchasing decisions.
- Scope
- U.S. customer base
- Materiality
- medium
Revenue recognition timing
Quarterly revenue comparability
Discontinued operations
Segment and consolidated comparability
Goodwill impairment
Non-cash earnings volatility
Contingent consideration and fair value estimates
Reported earnings and balance sheet values
: 28.4.2026